Increases of mean fluorescence intensity reflecting surface expression level of αIIbβ3 and CD42b by K562 cells after treatment by PHA/PMA/act D- or PHA/act D-generated MVs
. | PHA + PMA + act D . | . | PHA + act D . | . | ||
---|---|---|---|---|---|---|
. | βIIbβ3 . | CD42b . | αIIbβ3 . | CD42b . | ||
Control cells | 53.3 ± 4.6 | 63.4 ± 8.9 | 33.2 ± 1.7 | 55.7 ± 9.6 | ||
MV | ||||||
1 μg/mL | 403.8 ± 40.2* | 81.4 ± 26.7 | ND | ND | ||
5 μg/mL | 493.3 ± 58.3† | 113.6 ± 9.2* | 56.7 ± 7.8 | 78.9 ± 22.3 | ||
10 μg/mL | 680.2 ± 62.5† | 286.7 ± 45.2* | 78.9 ± 8.4* | 106.4 ± 22.9* |
. | PHA + PMA + act D . | . | PHA + act D . | . | ||
---|---|---|---|---|---|---|
. | βIIbβ3 . | CD42b . | αIIbβ3 . | CD42b . | ||
Control cells | 53.3 ± 4.6 | 63.4 ± 8.9 | 33.2 ± 1.7 | 55.7 ± 9.6 | ||
MV | ||||||
1 μg/mL | 403.8 ± 40.2* | 81.4 ± 26.7 | ND | ND | ||
5 μg/mL | 493.3 ± 58.3† | 113.6 ± 9.2* | 56.7 ± 7.8 | 78.9 ± 22.3 | ||
10 μg/mL | 680.2 ± 62.5† | 286.7 ± 45.2* | 78.9 ± 8.4* | 106.4 ± 22.9* |